- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jordyn Sava | Authors
Lacrotrectinib Leads to Prolonged Response in NTKR+ Tumors
June 05, 2022
Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.
Ivosidenib Plus Azacitidine Yields Significant Treatment Benefit in IDH1-Mutant AML
June 04, 2022
Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.
Avelumab Up Front Plus BSC Prolongs OS in Advanced Urothelial Carcinoma Over BSC Alone
May 25, 2022
The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.
Statistically Significant EFS Boost Observed With Nivolumab/Chemo for Resectable NSCLC
April 12, 2022
Results of a phase 3 trial comparing neoadjuvant nivolumab plus chemotherapy denoted benefit vs chemotherapy alone for patients with resectable non-small cell lung cancer.
H3K27M+ Diffuse Intrinsic Pontine Gliomas Derive Benefit from GD2-Directed CAR T-cell Therapy
April 11, 2022
Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.